FDA Approves New Non-Opioid Painkiller

The Food and Drug Administration (FDA) has approved Vertex Pharmaceuticals’ non-opioid painkiller pill, Journavx, a new alternative for pain relief that comes without the risk of addiction. This milestone comes after a long history of mostly unsuccessful efforts to develop painkillers without the destructive dependency of cheap and widely available opioids, which have caused a horrific epidemic of abuse and overdose in the U.S.

A New Standard of Care

Vertex’s drug is specifically approved for the treatment of moderate-to-severe acute pain, which is usually caused by injury, surgery, illness, trauma, or painful medical procedures and likely eases with time. Around 80 million patients are prescribed a medicine for their moderate-to-severe acute pain every year in the U.S.

“We have the opportunity to change the paradigm of acute pain management and establish a new standard of care,” said Dr. Reshma Kewalramani, Vertex CEO.

How Journavx Works

Journavx works by blocking pain signals at their origin before they reach the brain. This is different from opioids, which act directly on the brain to block pain, triggering the brain’s rewards centers in a way that can feed addiction.

Efficacy and Safety

The painkiller was more effective than placebo at reducing the intensity of pain after 48 hours in two late-stage studies on more than 1,000 patients who had abdominoplasties (tummy tucks) and roughly another 1,000 in people who had bunion surgery. In both trials, rates of adverse side effects were lower in those who received Journavx compared to people who took a placebo. The most commonly reported adverse events among people who received Journavx were itching, muscle spasms, and rash, among others, according to the FDA.

Potential Market Opportunity

Vertex’s painkiller produced positive results in a mid-stage trial in diabetes patients suffering from a chronic nerve condition. The bigger opportunity for Vertex may be to win FDA approval in chronic pain, an area where the risk of addiction to prescription opioids can be greater, according to the Centers for Disease Control and Prevention.

Conclusion

The approval of Journavx marks a significant milestone in the development of non-opioid painkillers. With its unique mechanism of action, Journavx has the potential to change the way we approach acute pain management. As the company moves forward with plans to bring this innovative treatment to patients, it is poised to make a significant impact on the lives of millions of people around the world.

FAQs

Q: What is Journavx and how does it work?
A: Journavx is a non-opioid painkiller that works by blocking pain signals at their origin before they reach the brain.

Q: What is the typical use of Journavx?
A: Journavx is approved for the treatment of moderate-to-severe acute pain, which is usually caused by injury, surgery, illness, trauma, or painful medical procedures and likely eases with time.

Q: How effective is Journavx?
A: In two late-stage studies, Journavx was more effective than placebo at reducing the intensity of pain after 48 hours in patients who had abdominoplasties and bunion surgery.